Cas No.: | 912288-64-3 |
Chemical Name: | Glycine, N,N-diethyl-, 1-[5-[(1Z)-2-cyano-2-(3,4-dimethoxyphenyl)ethenyl]-2-thienyl]-4-piperidinyl ester |
Synonyms: | YHO13351 free base;YHO 13351 free base |
SMILES: | N#CC(=CC1SC(N2CCC(OC(=O)CN(CC)CC)CC2)=CC=1)C1C=C(OC)C(OC)=CC=1 |
Formula: | C26H33N3O4S |
M.Wt: | 483.6229 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo; YHO-13351 is rapidly converted into YHO-13177 after its oral or intravenous administration, significantly increases the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model coadministration of irinotecan. |